To acquire the complete package would stack the deck in any of the biopharmas, but until that deal is made (for which the phase 2a results have already provided efficacy data) licensing deals are an open market for profiteering IMHO.
With such a tightly jigged ship, their top priority of two licensing deals in 2014 can be assumed to come into play without notice.
BBY valued 0.12c low, 0.17c high on previous market knowledge, A "3-4 bagger".
Things have only improved for the company since then. . .
- Forums
- ASX - By Stock
- PAB
- quality, compiled.
quality, compiled., page-5
Featured News
Add PAB (ASX) to my watchlist
|
|||||
Last
0.6¢ |
Change
-0.001(14.3%) |
Mkt cap ! $12.34M |
Open | High | Low | Value | Volume |
0.6¢ | 0.6¢ | 0.6¢ | $1.953K | 325.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 4291214 | 0.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.7¢ | 500160 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 4291214 | 0.006 |
14 | 4949991 | 0.005 |
12 | 7264199 | 0.004 |
6 | 6065682 | 0.003 |
2 | 2770000 | 0.002 |
Price($) | Vol. | No. |
---|---|---|
0.007 | 500160 | 1 |
0.008 | 2092233 | 5 |
0.010 | 126000 | 2 |
0.011 | 680000 | 2 |
0.012 | 292407 | 2 |
Last trade - 11.14am 06/09/2024 (20 minute delay) ? |
Featured News
PAB (ASX) Chart |